In this photo provided by An Khoun Sam Aun/Ministry of Information of Cambodia, Cambodian Prime Minister Hun Sen attends during an online opening session of the Asia-Europe Meeting (ASEM) in Phnom Penh, Cambodia, Thursday, Nov. 25, 2021. Hun Sen on Thursday welcomed leaders of Asian and European nations to the 13th biennial Asia-Europe Meeting, held virtually and postponed from last year due to the coronavirus pandemic. (An Khoun Sam Aun/Ministry of Information of Cambodia via AP)
PHNOM PENH, Cambodia (AP) — Cambodian Prime Minister Hun Sen opened a virtual meeting of Asian and European leaders Thursday with a call for sustainable and shared global growth as the world seeks to recover from the COVID-19 pandemic.
Thirty European countries and 21 Asian countries, along with multinational organizations representing the European Union and the Association of Southeast Asian Nations, are represented at the two-day Asia-Europe Meeting. The biennial event is being hosted by Cambodia after being postponed from last year due to the pandemic.
ASEM's membership accounts for 65% of the global economy, 60% of the world’s population, 75% of global tourism and and 55% of global trade, according to the organizers.
“As we all strive for socio-economic recovery while living with COVID-19, the theme that we have chosen for the ASEM-13, namely “Strengthening Multilateralism for Shared Growth,” is even more valid and relevant than ever,” Hun Sen said in opening remarks to the meeting. “In fact, in the post-COVID-19 crisis world, we need to further reinforce our Asia-Europe partnership to maintain a strong multilateralism that will bring about a global growth that is not only ‘Sustainable’ but can also be ‘Shared.’”
The absence of one leader, Myanmar’s Senior Gen. Min Aung Hlaing, is likely to reduce attention at ASEM to the deterioration of human rights in that Southeast Asian country since the army seized power in February from the elected government of Aung San Suu Kyi.
According to the list of attendees, Myanmar’s representation is listed as “working group.” There has been no public explanation of Min Aung Hlaing’s absence, but his military-installed government is ostracized by many Western nations for its takeover and its violent suppression of pro-democracy protests. U.N. experts have said the country is now on the verge of civil war.
There had been concerns that if the Myanmar leader had attended, major Western powers would have downgraded their representation, diminishing the prospects for substantive cooperation.
It is the third time that Min Aung Hlaing, who led February’s army takeover, has been absent from important regional meetings which Myanmar's leader would normally attend.
The Association of Southeast Asian Nations, of which Myanmar is a member, last month agreed not to invite him to its annual summit meeting. The action was a rebuke for Myanmar’s failure to cooperate with ASEAN’s modest efforts to help restore peace and stability to the strife-torn country. Myanmar was invited to send a representative in Min Aung Hlaing’s place but declined to do so.
The general was also absent from the ASEAN-China Special Summit earlier this week.7 Pharmaceutical Stocks to Buy For a Healthy Portfolio in 2022
One year ago, investors expected 2021 to be a huge year for pharmaceutical stocks. The bullish perspective was that as vaccines rolled out and the economy reopened, investors would shift from biotech stocks to traditional pharmaceutical stocks.
But the Delta variant has kept Covid-19 top of mind for many investors. While it’s true that some pharmaceutical stocks were part of the vaccine race, other players in the space have not performed as well as was hoped. Case in point, as of October 6, 2021, the iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) is up only 9.7% in the last 12 months. And if you bought shares of the fund at the beginning of the year, you have no growth to show for your patience.
There are reasons beyond Covid-19 to consider when assessing the disappointing performance of pharmaceutical stocks. One is the current political climate which is making no secret of its desire to reshape the healthcare industry. And it has the pricing practices of “big pharma” firmly in its crosshairs.
However, the pharmaceutical sector is still loaded with quality stocks for investors who are willing to accept the inherent risk. And that’s the focus of this special presentation. In the next few minutes, we’ll take a look at seven pharmaceutical stocks that
are ready to make strong moves forward in 2022.View the "7 Pharmaceutical Stocks to Buy For a Healthy Portfolio in 2022"